Abstract
Adenosine reduces opioid withdrawal symptoms by activating A1 adenosine receptors, probably by inhibiting excitatory amino acid release. Since blockade of A2A adenosine receptors seems to enhance dopaminergic striatopallidal transmission, we evaluated the role of the purinergic system in the opiate withdrawal syndrome by using two A1 receptor agonists [N 6-cyclohexyladenosine, CHA and 2-chloro-N 6-cyclopentyladenosine, CCPA], and two A2A receptor antagonists (SCH 58261 and 8-(3-chlorostyryl)caffeine, CSC).
Male adult rats received increasing doses of morphine sulphate suspended in 5 ml/kg of a sustained release preparation (40–100 mg/kg s.c.) daily for 4 days and 20 h after the last administration, the withdrawal syndrome was evoked by naloxone (5 mg/kg i.p.). Animals were observed for 30 min for signs of opiate withdrawal. Other groups of rats were implanted with concentric probes for microdialysis and dopamine levels were measured in the nucleus accumbens. CHA and CCPA (0.05, 0.1 or 0.5 mg/kg i.p.) significantly reduced "wet-dog" shakes, diarrhoea, teeth chattering, jumping and writhing. SCH 58261 and CSC (0.1, 0.5 or 1 mg/kg i.p.), given 10 min before naloxone, also reduced signs of opiate withdrawal. CHA plus SCH 58261 and CCPA plus CSC greatly enhanced the reduction of withdrawal signs observed with CHA and CCPA or CSC and SCH 58261 alone. In vivo microdialysis showed that naloxone significantly decreased DA release; this effect was prevented by pretreatment with systemic SCH 58261 and CSC, but not with CHA and CCPA. Our results demonstrate that A1 and A2A adenosine receptors mediate the effect induced by adenosine in opiate withdrawal syndrome and suggest that adenosine A1 agonists and adenosine A2A antagonists may be beneficial in the treatment of this syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acquas E, Carboni E, Di Chiara G (1991) Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur J Pharmacol 193:133–138
Aghajanian GK, Kogan JH, Moghaddam B (1994) Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res 636:126–132
Baraldi PG, Cacciari V, Spalluto G, Pineda de las Infantas y Villatoro MJ, Zocchi C, Dionisotti S, Ongini E (1996) Pyrazolo-(4,3-e)1,2,4-triazolo (1,5-c) pyrimidine derivates: potent and selective A2A adenosine antagonists. J Med Chem 39:1164–1171
Baumeister AA, Richard AL, Richmond-Landeche L, Hurry MJ, Waguespack AM (1992) Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome. Neuropharmacology 9:835–841
Coupar IM, Tran BL (2001) Withdrawal and bidirectional cross-withdrawal responses in rats treated with adenosine agonists and morphine. Life Sci 69:779–790
De Vries TJ, Schoffelmeer AN, Binnekade R, Vanderschuren LJ (1999) Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of iv drug self-administration. Psychopharmacology (Berl) 143:254–60
Di Chiara G (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95–137. Erratum in: Drug Alcohol Depend 39:155 (1995)
Di Chiara G, Imperato A (1988) Opiates, alcohol and barbiturates preferentially stimulate dopamine-release in the limbic system: studies with brain dialysis in freely-moving rats. Ann NY Acad Sci 24:125–131
Dionyssopoulos T, Hope W, Coupar IM (1992) Effect of adenosine analogues on the expression of opiate withdrawal in rats. Pharmacol Biochem Behav 42:201–206
Druhan JP, Walters CL Aston-Jones G (2000) Behavioral activation induced by D2-like receptor stimulation during opiate withdrawal. J Pharmacol Exp Ther 294:531–538
El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM (2001) Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 134:68–77
Feng YZ, Zhang RW, Rockhold RW, Ho IK (1995) Increased locus coeruleus glutamate levels are associated with naloxone-precipitated withdrawal from butorphanol in the rat. Neurochem Res 20:675–680
Ferrè S, Fuxe K, von Euler G, Johansson B, Fredhoml BB (1992) Adenosine, dopamine interactions in the brain. Neuroscience 51:501–512
Gomaa AA, Moustafa SA, Farghali AA (1989) Adenosine triphosphate blocks opiate withdrawal symptoms in rats and in mice. Pharmacol Toxicol 64:111–115
Hutson PH, Sarna GS, Kantamanemi BD, Curzon G (1985) Monitoring the effect of a tryptophan load on brain indole metabolism in freely moving rats by simultaneous cerebrospinal and brain dialysis. J Neurochem 44:1266–1273
Jacobson KA, Nikodijevic O, Padgett WL, Gallo-Rodriguez C, Maillard M, Daly JW (1993) 8-(3-Chlorostyryl)caffeine (SCH 58261) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett 323:141–144
Jaffe JH (1990) Drug addiction and drug abuse In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The pharmacological basis of therapeutics. Pergamon Press, New York, pp 552–573
Koob GF (2000) Neurobiology of addiction toward the development of new therapies. Ann N Y Acad Sci 909:170–85
Krystal JH Rasmussen K, Aghajanian GK (1990) Excitatory amino acid antagonists for opiate withdrawal (abstract). Am Psych Assoc Abstr 143:262
Michalska E, Malec D (1993) Agonist and antagonist of adenosine receptors and morphine withdrawal syndrome in rats. Pol J Pharmacol 45:1–9
Ongini E, Fredholm BB (1996) Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 17:364–372
Paxinos G, Watson C (1986) The rat brain in the stereotaxic coordinates, 2nd Edn. Academic Press, San Diego
Pothos E, Rada P, Mark GP, Hoebel BG (1991) Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 566:348–350
Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein P (1991) NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 197:9–16
Rossetti ZL, Melis L, Carboni S, Gessa GL (1990) Dopamine release in tolerance and withdrawal from morphine or ethanol (abstract). Neurosci Lett 39:S184
Salem A, Hope W (1999) Role of endogenous adenosine in the expression of opiate withdrawal in rats. Eur J Pharmacol 369:39–42
Stanishevskaia AV, Khristoliubova NA,Vekshina NL, Varfolomeev SO, Anokhina IP (1991) The action of low doses of bromocryptin in experimental morphine abstinence in rats. Farmakol Toksikol 54:15–17
Stella L, de Novellis V, Maione S, Leyva J, D'Amico M, Berrino L, Filippelli A, Rossi F (1995) Relationship between purinergic and glutamatergic systems in the opiate withdrawal syndrome. Res Commun Mol Path Pharmacol 87:55–56
Stella L, de Novellis V, Maione S, Marabese I, Rossi F (1997) Role of A1 and A2A adenosine receptors in the opiate withdrawal syndrome. Res Commun Alcohol Subst Abuse18:141–148
Tanganelli S Antonelli T Morari M, Bianchi C Beani L (1991) Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci Lett 122:270–272
Tidey JW, Miczek KA (1992) Morphine withdrawal aggression: modification with D1 and D2 receptor agonists. Psychopharmacol 108:177–184
Tokuyama S, Wakabayashi H, Ho IK (1996) Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur J Pharmacol 295:123–129
Tokuyama S, Takahashi M, Yamamoto T (2000) On the role of glutamate within the locus coeruleus during the development of opioid dependence and on the expression of withdrawal from dependence on opioids. Nihon Shinkei Seishin Yakurigaku Zasshi 20:141–7
Trujillo K, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85–89
Tse SYH, Wei ET (1986) Inhibition of the shake response in rats by adenosine and 2-chloroadenosine. Psychopharmacology 90:322–326
Wise RA, Bozarth MA (1982) Action of drugs abuse on brain reward system: an update with specific attentions to opiates. Pharmacol Biochem Behav 17:239–243
Zhang T, Feng YZ, Rockhold RW, Ho IK (1994) Naloxone-precipitated morphine withdrawal increases pontaine glutamate levels in the rat. Life Sci 55:25–31
Zhu H, Barr GA (2001) Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age-dependent. Synapse 40:282–293
Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S (1996a) The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2A adenosine receptor antagonist. J Pharmacol Exp Ther 276:398–404
Zocchi C, Ongini E, Ferrara S, Baraldi PG, Dionisotti S (1996b) Binding of the radioligand (3H)-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist to rat striatal membranes. Br J Pharmacol 117:1381–1386
Acknowledgements
We acknowledge Shering Plough SpA, Milan, Italy for the drug SCH 58261. This study is supported by "MIUR and Ricerca di Ateneo" grants. We are grateful to Jean Ann Gilder (Scientific Communication) for revising the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
L. Stella and V. de Novellis share first authorship
Rights and permissions
About this article
Cite this article
Stella, L., de Novellis, V., Vitelli, M.R. et al. Interactive role of adenosine and dopamine in the opiate withdrawal syndrome. Naunyn-Schmiedeberg's Arch Pharmacol 368, 113–118 (2003). https://doi.org/10.1007/s00210-003-0773-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-003-0773-9